Detailed instruction manual for Dasatinib/Startaxil tablets

Dasatinib is an oral targeted drug that is widely used in the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). As a second-generation BCR-ABL tyrosine kinase inhibitor, dasatinib can not only be used in newly diagnosed patients, but also provide an effective treatment option for patients who are resistant or intolerant to imatinib (Imatinib) or other treatment options. This article will introduce in detail the indications, usage and dosage, side effects, storage and pharmacological effects of dasatinib to help patients and medical staff fully understand the drug.

1. Indications and available groups

Dasatinib is suitable for adults and some pediatric patients, but it is unclear whether it is safe and effective in children under one year old.

1. Chronic myeloid leukemia (CML)

Dasatinib can be used as the initial treatment for adult patients with newly diagnosed Ph+CML in the chronic phase (CP). At the same time, dasatinib has also been proven to have good efficacy for patients with chronic, accelerated, myeloid or lymphoblastic stage CML who have previously received treatment including imatinib and developed resistance or intolerance. Its mechanism of action can overcome some drug-resistant mutations and inhibit the proliferation of leukemia cells.

2. Acute lymphoblastic leukemia (ALL)

Dasatinib is suitable for patients with Philadelphia chromosome-positive (Ph+) ALL, especially those who have developed resistance or intolerance to previous treatments. In addition, dasatinib can also be used in combination with chemotherapy for newly diagnosed Ph+ ALL patients, thereby improving the treatment success rate and disease remission rate.

2. Side effects of dasatinib

Common side effects of dasatinib involve multiple systems, including the blood system, cardiopulmonary system, and digestive system. Common symptoms include pleural effusion, diarrhea, headache, bleeding, fatigue, fever, rash, infection, nausea, dyspnea, cough, abdominal pain, vomiting and musculoskeletal pain. Swelling of the face, arms, and legs are also symptoms patients need to watch out for.

In addition, rare but serious adverse reactions reported after clinical marketing include atrial fibrillation or atrial flutter, thrombotic microangiopathy, interstitial lung disease, Stevens-Johnson syndrome, nephrotic syndrome, hepatitis B virus reactivation and liver function damage. Therefore, during treatment, patients need to regularly monitor electrocardiograms, blood indicators, and liver and kidney functions in order to detect and deal with potential risks in a timely manner.

3. Usage and dosage

1. Adult dosage

Chronic phaseCML: 100mg once daily;

Accelerated phaseCML, myeloid or lymphoblastic phase CML, Ph+ALL: 140 mg once daily.

2. Medication dosage for children

Weight10-19kg: 40mg per day; 20-29kg: 60mg per day; 30-44kg: 70mg per day; weight ≥45kg: 100mg per day; children's dosage needs to be recalculated according to weight every 3 months or more frequently according to weight changes, and adjusted under the guidance of a doctor.

3. Medication Management

Dasatinib is an oral tablet that can be taken once daily with or without food. Tablets must be swallowed whole and not crushed, cut or chewed. If children or some adult patients are unable to swallow the whole tablet, they should consult their doctor to develop a suitable medication plan. When handling broken or crushed tablets, wear latex or nitrile gloves to avoid direct contact with the medication.

4. Storage method

Dasatinib should be stored between 20°C and 25°C (68°F and 77°F), with an acceptable range of 15°C and 30°C (59°F and 86°F). Avoid moisture, heat or direct sunlight, and keep out of the reach of children.

5. Mechanism of action

Dasatinib can bind to multiple conformations of ABL kinase and has inhibitory effects on both imatinib-sensitive and resistant leukemia cells. Its mechanism of action includes inhibiting BCR-ABL overexpression, overcoming drug resistance caused by domain mutations, blocking the activation of alternative signaling pathways of SRC family kinases (LYN, HCK), and remaining active against cell lines overexpressing multidrug resistance genes. This enables it to be used clinically in newly diagnosed and drug-resistant leukemia patients, significantly inhibiting leukemia cell growth and delaying disease progression.

6. Risk of overdose

Clinical experience with overdose of dasatinib is limited. Individual cases show that daily doses of up to Patients taking 280 mg for one week developed severe myelosuppression and bleeding. Animal experiments have also shown that acute overdose can cause cardiotoxicity, such as ventricular necrosis and valvular/ventricular/atrial hemorrhage. Experiments on monkeys have shown that high doses can cause an increase in blood pressure. If overdose occurs, hematological indicators and cardiac function should be monitored immediately, and necessary supportive treatment should be taken.

7. Banned groups

It is contraindicated in patients allergic to dasatinib or structurally similar drugs. In addition, it should be used with caution or avoided in pediatric patients with severe cardiovascular disease or who have not been evaluated by a physician.

8. Summary

Dasatinib, as a second-generation tyrosine kinase inhibitor for the treatment of Ph+CML and Ph+ALL, provides an important treatment option for drug-resistant or newly diagnosed patients. Through standardized dosage, strict medication management, regular monitoring and individualized adjustments, disease progression can be effectively delayed and patient survival rates improved. At the same time, vigilance and reasonable handling of side effects are also key to ensuring long-term efficacy and safety. While using dasatinib, patients should maintain close communication with their doctors and regularly check heart, liver and kidney function and blood indicators to ensure drug safety and maximize efficacy.

Reference materials:https://go.drugbank.com/drugs/DB01254